Skip NavigationSkip to Content

Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans

  1. Author:
    Fernandes, Bruna
    Roy, Jyoti
    Basuli, Falguni
    Warner, Blake M
    Lindenberg, Liza
    Mena, Esther
    Adler, Steven S
    Griffiths,Gary
    Choyke, Peter L
    Lin, Frank I
  2. Author Address

    Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Chemistry and Synthesis Center, National Heart, Lung and Blood Institute, Bethesda, MD, United States., Salivary Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States., Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.,
    1. Year: 2024
    2. Date: Apr 23
    3. Epub Date: 2024 04 23
  1. Journal: Frontiers in Oncology
    1. 14
    2. Pages: 1367962
  2. Type of Article: Article
  3. Article Number: 1367962
  1. Abstract:

    Prostate-specific membrane antigen (PSMA) is present in high amounts in salivary glands, but it is unclear whether labeled binders of PSMA are excreted in the saliva. Ten patients with prostate cancer underwent whole-body [18F]DCFPyL PET/CT (NCT03181867), and saliva samples were collected between 0-120 minutes post-injection. [18F]DCFPyL salivary excretion was measured over 120 minutes and expressed as %ID/g. Protein-associated binding was estimated by the percentage of [18F]DCFPyL versus parent radiotracer. All PET scans of 10 patients (69 ± 8 years) with histologically confirmed prostate cancer (PSA= 2.4 ± 2.4, and Gleason Grade = 6-9) showed high uptake of [18F]-DCFPyL in salivary glands while 8 patients demonstrated high uptake in the saliva at 45 minutes. The intact [18F]-DCFPyL (98%) was also confirmed in the saliva samples at 120 min with increasing salivary radioactivity between 30-120 min. Systemically injected [18F]DCFPyL shows salivary gland uptake, an increasing amount of which is secreted in saliva over time and is not maximized by 120 minutes post-injection. Although probably insignificant for diagnostic studies, patients undergoing PSMA-targeted therapies should be aware of radioactivity in saliva. Copyright © 2024 Fernandes, Roy, Basuli, Warner, Lindenberg, Mena, Adler, Griffiths, Choyke and Lin.

    See More

External Sources

  1. DOI: 10.3389/fonc.2024.1367962
  2. PMID: 38715784
  3. PMCID: PMC11074343

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel